Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 8Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Brain Neoplasms 2Urothelial Carcinoma of the Bladder 1Sarcoma 1Oligodendroglioma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Muscle-invasive Urothelial Cancer of the Bladder 1Mouth Neoplasms 1Lymphoma, Follicular 1Laryngeal Neoplasms 1Glioma 1Giant Cell Tumor of Bone 1Ganglioneuroblastoma 1Estrogen Receptor Positive Breast Cancer 1Craniopharyngioma 1Carcinoma 1Astrocytoma 1Alzheimer Disease 1

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 13Cisplatin 13pembrolizumab 10Radiotherapy, Intensity-Modulated 9Carboplatin 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Cetuximab 7Radiotherapy 5Radiation 5Paclitaxel 5Biopsy 5Taxes 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Docetaxel 3ipatasertib 2durvalumab 2X-Rays 2Surgical Procedures, Operative 2Standard of Care 2Interviews as Topic 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Drug Therapy 2Disulfides 2Chemoradiotherapy 2trametinib 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Laryngeal Neoplasms × Transurethral Resection of Bladder × 1 year × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡